TY - JOUR AU - Alinari, L. AU - Blum, K. A. PY - 2016 DA - 2016// TI - How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2015-10-671826 DO - 10.1182/blood-2015-10-671826 ID - Alinari2016 ER - TY - JOUR AU - Castagna, L. AU - Bramanti, S. AU - Devillier, R. AU - Sarina, B. AU - Crocchiolo, R. AU - Furst, S. PY - 2017 DA - 2017// TI - Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma JO - Bone Marrow Transplant. VL - 52 UR - https://doi.org/10.1038/bmt.2017.26 DO - 10.1038/bmt.2017.26 ID - Castagna2017 ER - TY - JOUR AU - Gauthier, J. AU - Castagna, L. AU - Garnier, F. AU - Guillaume, T. AU - Socie, G. AU - Maury, S. PY - 2017 DA - 2017// TI - Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy JO - Bone Marrow Transplant VL - 52 UR - https://doi.org/10.1038/bmt.2016.349 DO - 10.1038/bmt.2016.349 ID - Gauthier2017 ER - TY - JOUR AU - Herbaux, C. AU - Gauthier, J. AU - Brice, P. AU - Drumez, E. AU - Ysebaert, L. AU - Doyen, H. PY - 2017 DA - 2017// TI - Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma JO - Blood VL - 129 UR - https://doi.org/10.1182/blood-2016-11-749556 DO - 10.1182/blood-2016-11-749556 ID - Herbaux2017 ER - TY - JOUR AU - Muenst, S. AU - Hoeller, S. AU - Dirnhofer, S. AU - Tzankov, A. PY - 2009 DA - 2009// TI - Increased programmed death-1 + tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival JO - Hum Pathol VL - 40 UR - https://doi.org/10.1016/j.humpath.2009.03.025 DO - 10.1016/j.humpath.2009.03.025 ID - Muenst2009 ER - TY - JOUR AU - Chen, B. J. AU - Chapuy, B. AU - Ouyang, J. AU - Sun, H. H. AU - Roemer, M. G. AU - Xu, M. L. PY - 2013 DA - 2013// TI - PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0855 DO - 10.1158/1078-0432.CCR-13-0855 ID - Chen2013 ER - TY - JOUR AU - Roemer, M. G. AU - Advani, R. H. AU - Ligon, A. H. AU - Natkunam, Y. AU - Redd, R. A. AU - Homer, H. PY - 2016 DA - 2016// TI - PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.66.4482 DO - 10.1200/JCO.2016.66.4482 ID - Roemer2016 ER - TY - JOUR AU - Ansell, S. M. PY - 2017 DA - 2017// TI - Nivolumab in the treatment of Hodgkin Lymphoma JO - Clin Cancer Res. VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-1387 DO - 10.1158/1078-0432.CCR-16-1387 ID - Ansell2017 ER - TY - JOUR AU - Johnson, D. B. AU - Balko, J. M. AU - Compton, M. L. AU - Chalkias, S. AU - Gorham, J. AU - Xu, Y. PY - 2016 DA - 2016// TI - Fulminant myocarditis with combination immune checkpoint blockade JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1609214 DO - 10.1056/NEJMoa1609214 ID - Johnson2016 ER - TY - JOUR AU - Ansell, S. M. AU - Lesokhin, A. M. AU - Borrello, I. AU - Halwani, A. AU - Scott, E. C. AU - Gutierrez, M. PY - 2015 DA - 2015// TI - PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411087 DO - 10.1056/NEJMoa1411087 ID - Ansell2015 ER - TY - JOUR AU - Younes, A. AU - Santoro, A. AU - Shipp, M. AU - Zinzani, P. L. AU - Timmerman, J. M. AU - Ansell, S. PY - 2016 DA - 2016// TI - Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30167-X DO - 10.1016/S1470-2045(16)30167-X ID - Younes2016 ER - TY - JOUR AU - Villasboas, J. C. AU - Ansell, S. M. AU - Witzig, T. E. PY - 2016 DA - 2016// TI - Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.7177 DO - 10.18632/oncotarget.7177 ID - Villasboas2016 ER - TY - JOUR AU - Yared, J. A. AU - Hardy, N. AU - Singh, Z. AU - Hajj, S. AU - Badros, A. Z. AU - Kocoglu, M. PY - 2016 DA - 2016// TI - Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation JO - Bone Marrow Transplant VL - 51 UR - https://doi.org/10.1038/bmt.2015.346 DO - 10.1038/bmt.2015.346 ID - Yared2016 ER - TY - JOUR AU - Angenendt, L. AU - Schliemann, C. AU - Lutz, M. AU - Rebber, E. AU - Schulze, A. B. AU - Weckesser, M. PY - 2016 DA - 2016// TI - Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation JO - Bone Marrow Transplant VL - 51 UR - https://doi.org/10.1038/bmt.2015.266 DO - 10.1038/bmt.2015.266 ID - Angenendt2016 ER - TY - JOUR AU - Onizuka, M. AU - Kojima, M. AU - Matsui, K. AU - Machida, S. AU - Toyosaki, M. AU - Aoyama, Y. PY - 2017 DA - 2017// TI - Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation JO - Int J Hematol. VL - 106 UR - https://doi.org/10.1007/s12185-017-2181-9 DO - 10.1007/s12185-017-2181-9 ID - Onizuka2017 ER - TY - JOUR AU - Singh, A. K. AU - Porrata, L. F. AU - Aljitawi, O. AU - Lin, T. AU - Shune, L. AU - Ganguly, S. PY - 2016 DA - 2016// TI - Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma JO - Bone Marrow Transplant VL - 51 UR - https://doi.org/10.1038/bmt.2016.111 DO - 10.1038/bmt.2016.111 ID - Singh2016 ER - TY - JOUR AU - Oshima, Y. AU - Tanimoto, T. AU - Yuji, K. AU - Tojo, A. PY - 2017 DA - 2017// TI - Association between GvHD and nivolumab in the FDA adverse event reporting system JO - Bone Marrow Transplant VL - 52 UR - https://doi.org/10.1038/bmt.2017.158 DO - 10.1038/bmt.2017.158 ID - Oshima2017 ER - TY - JOUR AU - Blazar, B. R. AU - Carreno, B. M. AU - Panoskaltsis-Mortari, A. AU - Carter, L. AU - Iwai, Y. AU - Yagita, H. PY - 2003 DA - 2003// TI - Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism JO - J Immunol. VL - 171 UR - https://doi.org/10.4049/jimmunol.171.3.1272 DO - 10.4049/jimmunol.171.3.1272 ID - Blazar2003 ER - TY - STD TI - Haverkos BM, Schowinksy J, Kaplan J, Kamdar M, Kanate AS, Saad A, et al. Checkpoint blockade for treatment of relapsed lymphoma following allogeneic hematopoietic cell transplant: use may be complicated by onset of severe acute graft versus host disease. Blood. 2016; 128: 1163. http://www.bloodjournal.org/content/128/22/1163. UR - http://www.bloodjournal.org/content/128/22/1163 ID - ref19 ER - TY - JOUR AU - Merryman, R. W. AU - Kim, H. T. AU - Zinzani, P. L. AU - Carlo-Stella, C. AU - Ansell, S. M. AU - Perales, M. A. PY - 2017 DA - 2017// TI - Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma JO - Blood VL - 129 UR - https://doi.org/10.1182/blood-2016-09-738385 DO - 10.1182/blood-2016-09-738385 ID - Merryman2017 ER - TY - JOUR AU - Stevens, A. M. AU - Sullivan, K. M. AU - Nelson, J. L. PY - 2003 DA - 2003// TI - Polymyositis as a manifestation of chronic graft-versus-host disease JO - Rheumatology (Oxford) VL - 42 UR - https://doi.org/10.1093/rheumatology/keg025 DO - 10.1093/rheumatology/keg025 ID - Stevens2003 ER - TY - JOUR AU - Platzbecker, U. AU - Klingel, K. AU - Thiede, C. AU - Freiberg-Richter, J. AU - Schuh, D. AU - Ehninger, G. PY - 2001 DA - 2001// TI - Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin JO - Bone Marrow Transplant VL - 27 UR - https://doi.org/10.1038/sj.bmt.1702744 DO - 10.1038/sj.bmt.1702744 ID - Platzbecker2001 ER - TY - JOUR AU - Rackley, C. AU - Schultz, K. R. AU - Goldman, F. D. AU - Chan, K. W. AU - Serrano, A. AU - Hulse, J. E. PY - 2005 DA - 2005// TI - Cardiac manifestations of graft-versus-host disease JO - Biol Blood Marrow Transplant VL - 11 UR - https://doi.org/10.1016/j.bbmt.2005.07.002 DO - 10.1016/j.bbmt.2005.07.002 ID - Rackley2005 ER - TY - JOUR AU - Rouah, E. AU - Gruber, R. AU - Shearer, W. AU - Armstrong, D. AU - Hawkins, E. P. PY - 1988 DA - 1988// TI - Graft-versus-host disease in the central nervous system. A real entity? JO - Am J Clin Pathol. VL - 89 UR - https://doi.org/10.1093/ajcp/89.4.543 DO - 10.1093/ajcp/89.4.543 ID - Rouah1988 ER - TY - JOUR AU - Linette, G. P. AU - Stadtmauer, E. A. AU - Maus, M. V. AU - Rapoport, A. P. AU - Levine, B. L. AU - Emery, L. PY - 2013 DA - 2013// TI - Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-03-490565 DO - 10.1182/blood-2013-03-490565 ID - Linette2013 ER - TY - JOUR AU - Raman, M. C. AU - Rizkallah, P. J. AU - Simmons, R. AU - Donnellan, Z. AU - Dukes, J. AU - Bossi, G. PY - 2016 DA - 2016// TI - Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy JO - Sci Rep. VL - 6 UR - https://doi.org/10.1038/srep18851 DO - 10.1038/srep18851 ID - Raman2016 ER - TY - JOUR AU - Cameron, B. J. AU - Gerry, A. B. AU - Dukes, J. AU - Harper, J. V. AU - Kannan, V. AU - Bianchi, F. C. PY - 2013 DA - 2013// TI - Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells JO - Sci Transl Med. VL - 5 UR - https://doi.org/10.1126/scitranslmed.3006034 DO - 10.1126/scitranslmed.3006034 ID - Cameron2013 ER - TY - JOUR AU - Moslehi, J. J. AU - Salem, J. E. AU - Sosman, J. A. AU - Lebrun-Vignes, B. AU - Johnson, D. B. PY - 2018 DA - 2018// TI - Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis JO - Lancet. VL - 391 UR - https://doi.org/10.1016/S0140-6736(18)30533-6 DO - 10.1016/S0140-6736(18)30533-6 ID - Moslehi2018 ER - TY - JOUR AU - Saha, A. AU - O’Connor, R. S. AU - Thangavelu, G. AU - Lovitch, S. B. AU - Dandamudi, D. B. AU - Wilson, C. B. PY - 2016 DA - 2016// TI - Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality JO - J Clin Invest. VL - 126 UR - https://doi.org/10.1172/JCI85796 DO - 10.1172/JCI85796 ID - Saha2016 ER - TY - JOUR AU - Boutros, C. AU - Tarhini, A. AU - Routier, E. AU - Lambotte, O. AU - Ladurie, F. L. AU - Carbonnel, F. PY - 2016 DA - 2016// TI - Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination JO - Nature reviews Clinical oncology. VL - 13 UR - https://doi.org/10.1038/nrclinonc.2016.58 DO - 10.1038/nrclinonc.2016.58 ID - Boutros2016 ER - TY - JOUR AU - Schilbach, K. AU - Schick, J. AU - Wehrmann, M. AU - Wollny, G. AU - Simon, P. AU - Schlegel, P. G. PY - 2007 DA - 2007// TI - PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers JO - Transplantation VL - 84 UR - https://doi.org/10.1097/01.tp.0000268074.77929.54 DO - 10.1097/01.tp.0000268074.77929.54 ID - Schilbach2007 ER - TY - JOUR AU - Juchem, K. W. AU - Sacirbegovic, F. AU - Zhang, C. AU - Sharpe, A. H. AU - Russell, K. AU - McNiff, J. M. PY - 2018 DA - 2018// TI - PD-L1 prevents the development of autoimmune heart disease in graft-versus-host disease JO - J Immunol. VL - 200 UR - https://doi.org/10.4049/jimmunol.1701076 DO - 10.4049/jimmunol.1701076 ID - Juchem2018 ER -